Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(24):1838-1840; doi:10.1093/jnci/93.24.1838
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fintor, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fintor, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 24, 1838-1840, December 19, 2001
© 2001 Oxford University Press

NEWS

Eastern European Drug Makers Are Newest Players in Volatile Market

Lou Fintor

Emerging from almost half a century of government ownership, newly privatized Central and Eastern Europe drug makers are poised to intensify competition in Western European and North American pharmaceutical markets.

But many in the drug industry are asking whether a foray into Western markets will lower prices for cancer patients or simply provide new "strategic partnerships," opening up extensive Eastern European distribution networks to large multinational brand name pharmaceuticals.

"We launched a new strategy to begin market operations in Europe and the United States in 1998 immediately after the Russian economic crisis," said Zsuzsa Beke, spokesperson for Eastern Europe’s oldest pharmaceutical house, Gedeon Richter, Ltd., Budapest, Hungary.

Of more than $262 million in total sales 2 years ago, $53 million came . . . [Full Text of this Article]

Fine Chemicals

Targeting EU Markets


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?